Clostridium difficile infection among kidney transplant recipients: frequency, clinical presentation, and outcome

Apmis ◽  
2014 ◽  
Vol 123 (3) ◽  
pp. 234-239 ◽  
Author(s):  
Sophia Lionaki ◽  
Konstantinos Panagiotellis ◽  
Demetrios Moris ◽  
George Daikos ◽  
Mina Psyhogiou ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Kidney Transplant ◽  
Clostridium Difficile Infection ◽  
Clinical Presentation ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Risk factors associated with Clostridium difficile infection in kidney transplant recipients

2018 ◽  
Vol 20 (4) ◽  
pp. e12918 ◽  
Author(s):  
M.L. Spinner ◽  
B.R. Stephany ◽  
P.M. Cerrato ◽  
S.W. Lam ◽  
E.A. Neuner ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clostridium Difficile ◽  
Kidney Transplant ◽  
Clostridium Difficile Infection ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Factors Associated

scholarly journals Tuberculosis Characterization in a Special Population of Kidney Transplant Recipients

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Barbara Reis-Santos ◽  
Ethel Leonor Noia Maciel
Keyword(s):  
Kidney Transplant ◽  
Clinical Presentation ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Careful Evaluation ◽  
Tb Control ◽  
Health History ◽  
Sociodemographic Data ◽  
Clinical Records ◽  
Active Disease

Setting. Tuberculosis clinical presentation is not typical in kidney transplant recipients and the diagnosis of active disease is usually delayed. Objective. To characterize tuberculosis presentation in Brazilian's kidney transplant recipients. Study Design. We analyzed the clinical records of tuberculosis cases regarding sociodemographic data and health history. Results. Thirteen TB cases were identified among 843 transplant recipients. The average time for TB development after transplantation was 4 years. Eight subjects presented pulmonary disease, seven patients required hospitalization Alertness to the possibility of TB and the careful evaluation for possible TB of all kidney transplant recipients with unexplained is vital, as is the related work of transplant and TB control teams and four died as a consequence of TB. Conclusion. The severe consequences of TB in posttransplantation can become critical.

scholarly journals Coronavirus disease 2019 in kidney transplant recipients: a systematic review and meta-analysis

2021 ◽  
Author(s):  
QY Ho ◽  
R Sultana ◽  
TL Lee ◽  
S Thangaraju ◽  
T Kee ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Clinical Presentation ◽  
Meta Analysis ◽  
Kidney Injury ◽  
High Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Presenting Symptoms ◽  
Effect Of Treatment ◽  
Dose Corticosteroid

Introduction: The clinical presentation and outcomes of coronavirus disease 2019 (COVID-19) in kidney transplant recipients (KTRs) have not been well studied. Methods: We performed a meta-analysis to examine the presenting features, outcomes and the effect of treatment on outcomes of KTRs with COVID-19. Database search was performed up to 5 September 2020 through PubMed, EMBASE, Web of Science, SCOPUS, and CENTRAL. Results: Overall, 23 studies (1373 patients) were included in the review and meta-analysis. The most common presenting symptoms included fever (74.0%, 95% confidence interval [CI] 65.3–81.1), cough (63.3% 95% CI 56.5–69.6) and dyspnoea (47.5%, 95% CI 39.6–55.6). Pooled rates of mortality and critical illness were 21.1% (95% CI 15.3-28.4) and 27.7% (95% CI 21.5–34.8) respectively. Acute kidney injury occurred in 38.9% (95% CI 30.6–48.1) and dialysis was required in 12.4% (95% CI 8.3–18.0) of the cases. Discussion: KTRs with COVID-19 have a similar clinical presentation as the general population but have higher morbidity and mortality. It is uncertain whether high dose corticosteroid or hydroxychloroquine reduces the risks of mortality in KTRs with COVID-19.

scholarly journals COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Sanjiv Jasuja ◽  
Gaurav Sagar ◽  
Anupam Bahl ◽  
Shalini Verma
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Clinical Presentation ◽  
Treatment Options ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Igg Antibody ◽  
Pharmacological Management ◽  
Overall Mortality

Introduction. Experience of COVID-19 in kidney transplant recipients (KTRs) with clinical presentation, management, factors influencing mortality, and antibody response is limited. Material and Methods. A retrospective data of COVID-19 in KTRs was collected and analyzed. The mortality rate, risk factors, and antibody response were primary objectives, while the clinical presentation, laboratory indicators, and pharmacological management were secondary objectives. Results. The 67 KTRs with polymerase chain reaction (PCR) confirmed COVID-19 infection reported between 1 May 2020 and 31 December 2020; 61.2% of patients were hospitalized; and 20.9% needed ventilation. The overall mortality was 26.9%, while blood group A had 50% mortality. The treatment options and used were steroids (100%), convalescent plasma (32.8%), ivermectin (58.2%), doxycycline (55.2%), remdesivir (34.3%), tocilizumab (10.4%), antibiotics (61.2%), anti-fungals (26.9%), low molecular weight heparin (45.3%), and oral anti-coagulants (26.9%). Anti-nucleosides (mycophenolate or azathioprine) were discontinued in 76.1% and calcineurin inhibitors (CNI) in 26.9%. Significant mortality ( p < 0.001 ) was observed in patients presenting with SpO2 <94 needing ICU care, ventilation, dialysis/acute kidney injury (AKI), and empirical therapies like convalescent plasma and remdesivir. The age of survivors versus nonsurvivors was not significantly different ( p = 0.02 ). The positive blood culture, low serum albumin, high TLC, high blood urea, interleukin-6, and CT severity score ≥15 were statistically significant in nonsurvivors. Overall mortality, mortality of hospitalized patients, and mortality of ventilated patients was 27%, 44%, and 100%, respectively. The median value of SARS-CoV-2 (COVID-19) IgG antibody was 68.60 (IQR, 28.5–94.25) AU/ml in more than 90% of survivors. Conclusion. KTRs with COVID-19, needing ICU care, dialysis and ventilation support had poor outcomes. Recovered patients mounted adequate antibody response.

scholarly journals Incidence, Risk Factors, and Outcomes of Clostridium difficile Infections in Kidney Transplant Recipients

2018 ◽  
Vol 102 (9) ◽  
pp. 1576-1581 ◽  
Author(s):  
George J. Li ◽  
Justin Trac ◽  
Shahid Husain ◽  
Olusegun Famure ◽  
Yanhong Li ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clostridium Difficile ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Incidence Risk
Sign in / Sign up

Export Citation Format

Share Document